Abstract
The authors evaluated the risk for fracture because of the development of osteoporosis in men with prostate cancer who were subjected to androgen deprivation therapy (ADT) in the clinical scenario of prostate-specific antigen relapse after local therapy with curative intent, such as radical prostatectomy or radiation therapy. To assess the risk of fracture, the World Health Organization Fracture Risk Calculation Tool (FRAX) was applied, and the data obtained were compared with the results of the standard bone mineral density (BMD) evaluation by dual-energy X-ray absorptiometry (DXA) scans and the objective T scores derived from DXA scans. ADT is known as a significant contributor of osteoporosis in men with prostate cancer (PCa), and once diagnosed, osteoporosis needs to be treated by bone-targeting approaches, whereas osteopenia might be managed by preventive and supportive measures. Comparison of Fracture Risk Assessment Tool Score to Bone Mineral Density for Estimating Fracture Risk in Patients With Advanced Prostate Cancer on Androgen Deprivation TherapyUrologyVol. 84Issue 1PreviewTo estimate the risk of fracture (Fracture Risk Assessment Tool [FRAX] algorithm) because of the development of osteoporosis in prostate cancer patients undergoing androgen deprivation therapy (ADT) for patients who would otherwise not have been identified for treatment by the T score. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
